Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

10x Genomics Q3 2026 Results: Net Loss of $19.4M, Loss Narrows

10x Genomics, Inc. reported its third quarter 2026 results, highlighting continued revenue growth driven by its spatial biology and single-cell analysis platforms. The company maintained its full-year revenue guidance while noting improvements in gross margins due to manufacturing efficiencies.

Watch the 10x Genomics, Inc. earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue150.7149.0
Gross profit112.9100.3
Profit before tax-18.5-28.2
Net income-19.4-27.5
EPS (diluted, $ a share)$-0.15$-0.22

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+1.1%
Gross margin75.0%
Operating margin-10.7%
Source

10-Q filed with the SEC, NASDAQ: TXG. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

10x Genomics, Inc.: key numbers

Share price
$54.99Close, Nov 16
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from 10x Genomics, Inc.

All →
4:54 PM ET Form 4
Insider Selling

10x Genomics CEO Serge Saxonov Sells $1.95M of Stock

Serge Saxonov, CEO, sold 31,000 shares of 10x Genomics, Inc. at $62.90 a share, worth $1.95M in total on Nov 10, 2026. Shares held after the trade: 1,019,249 (-3.0%).

Value
$1.95M
Shares
31,000
Price
$62.90
Role
CEO
Holding change
-3.0%
Trade date
Nov 10, 2026
4:10 PM ET 8-K
Financial Results

10x Genomics Financial Results

10x Genomics reported Q3 2026 revenue of $150.7 million, a 1% increase year-over-year, and narrowed its net loss to $19.4 million. The company began commercial shipments of its Atera platform and raised its full-year 2026 revenue guidance to a range of $625 million to $635 million.

Term
Q3 2026

“The biggest highlight of the quarter was the start of commercial shipments of Atera. Enthusiasm for the platform has continued to build, and we are incredibly excited to be putting instruments in customers’ hands. We were also encouraged with the results across our broader business, driven by continued strength in consumables.”

Serge Saxonov, Co-founder and CEO of 10x Genomics

“As biology is entering a new era of AI and data maximalism, 10x is positioned incredibly well to benefit and to be the key enabler of progress going forward.”

Serge Saxonov, Co-founder and CEO of 10x Genomics
4:06 PM ET 8-K
Executive Compensation

10x Genomics Executive Compensation

10x Genomics appointed Ansuman Satpathy and Joseph Gilliam to its Board of Directors as Class III directors. Both will receive compensation under the company's Non-Employee Director Compensation Policy, including an annual cash retainer of $60,000 and a one-time restricted stock unit grant valued at $400,000.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.